Metagenomi, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

5 Mar 2026

MGX

10-K: Metagenomi Therapeutics Reprioritizes Pipeline, Extends Cash Runway

Metagenomi Therapeutics, Inc. reported an increased net loss in 2025, alongside a strategic reprioritization of its pipeline, a 25% workforce reduction, and an extension of its cash runway into late 2027.

NASDAQ

17 Mar 2025

MGX

Metagenomi, INC

10-K: Metagenomi's 10-K Filing Reveals Progress in Gene Editing Pipeline, Hemophilia A Program Leads the Way

Metagenomi's 2024 10-K filing highlights advancements in its gene editing platform and progress in its lead Hemophilia A program, with plans for IND filings in 2026.

NASDAQ

27 Mar 2024

MGX

Metagenomi, INC

10-K: Metagenomi Outlines Comprehensive Genome Editing Platform in 10-K Filing

Metagenomi's 10-K filing details its proprietary metagenomics-derived genome editing toolbox and its strategy for developing curative genetic medicines.